More about

Forced Vital Capacity

News
April 03, 2025
3 min read
Save

Odds for bronchodilator responsiveness lower in afternoon vs. morning hours

The odds for bronchodilator responsiveness significantly fell among patients who underwent spirometry testing in the afternoon vs. morning, according to findings published in Thorax.

News
March 17, 2025
3 min read
Save

Wood dust exposure negatively impacts lung function in carpenters

Between a group of carpenters and an age-, sex- and height-matched group of university employees, carpenters had worse average lung function values, according to results published in BMC Pulmonary Medicine.

News
February 13, 2025
3 min read
Save

Individuals with impaired FEV1/FVC trajectories often experience wheeze before middle age

Around 20% to 25% of individuals with rapidly declining FEV1/FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The Lancet Respiratory Medicine.

News
February 13, 2025
1 min read
Save

Positive topline data reported in phase 3 trial of nerandomilast in progressive PF

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.

News
December 23, 2024
2 min read
Save

Children’s lung function improved with classroom, bedroom air purification

In a set of healthy school-aged children, several lung function measures, including FEV1 and FVC, improved with classroom plus bedroom air purification, according to results published in JAMA Pediatrics.

News
December 17, 2024
3 min read
Save

Deupirfenidone reduces FVC decline, well tolerated in IPF at 26 weeks

Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.

News
November 12, 2024
2 min read
Save

Topline results: AI-established IPF drug well-tolerated, improves FVC

Patients with idiopathic pulmonary fibrosis had improved FVC between baseline and 12 weeks with receipt of ISM001-055, a small molecule targeting Traf2- and Nck-interacting kinase, vs. placebo, according to topline results.

News
September 24, 2024
2 min read
Save

Early childhood exposure to more green spaces linked to improved lung function

Among school-age children, residence near more green spaces in early childhood positively impacted lung function, according to results published in Environment International.

News
September 17, 2024
1 min read
Save

Positive topline data reported in phase 3 trial of nerandomilast in adults with IPF

Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.

News
July 24, 2024
2 min read
Save

AI model correctly predicts FVC, FEV1 from chest X-rays

With just chest X-rays, an AI model estimated FVC and FEV1 and had “excellent agreement” when compared with spirometry results, according to results published in The Lancet Digital Health.

View more